急性心衰患者特征、管理与预后的时间趋势:两项重复快照研究
该研究通过2009年和2021年两项多中心快照调查(分别纳入1658例和1513例急性心衰住院患者),评估临床特征、诊疗及结局变化。结果显示合并症负担增加,急诊入院比例上升(64%→71%),重症监护入住率稳定(40%);射血分数降低患者出院时ACEI/ARB/ARNI处方率下降(77.8%→70.6%),而β受体阻滞剂和MRA使用增加;1个月和6个月死亡率分别从8.9%降至7.6%、24.7%降至21.3%,匹配后HR 0.78(0.66-0.94),但高龄和射血分数保留患者未见改善。
要点
- 急性心衰合并症负担增加,急诊入院比例上升,重症监护入住率稳定。
- 射血分数降低患者出院时ACEI/ARB/ARNI处方率下降,β受体阻滞剂和MRA使用增加。
- 短期死亡率显著下降,但高龄和射血分数保留患者未见改善。
核心结论
- 12年间急性心衰患者合并症负担增加,缺乏专用入院路径,出院时循证药物处方存在显著不足,但短期死亡率显著下降。
研究设计与样本
- 两项多中心快照调查,分别于2009年和2021年开展,采用相同方法,分别纳入1658例和1513例急性心衰住院患者。
主要发现
- 患者年龄和左心室射血分数(LVEF)分类比例基本不变(76岁,53%为射血分数降低)。
- 多数合并症患病率上升,急诊入院比例从64%升至71%,重症监护入住率稳定在40%。
- 射血分数降低患者出院时ACEI/ARB/ARNI处方率从77.8%降至70.6%,β受体阻滞剂从67.7%升至74.2%,MRA从26.6%升至35.5%。
- 1个月死亡率从8.9%降至7.6%,6个月死亡率从24.7%降至21.3%;匹配后HR 0.78(0.66-0.94)。
- 死亡率改善见于多数患者,但最高龄和射血分数保留患者未见改善。
关键数值与推荐
- 射血分数降低患者出院时ACEI/ARB/ARNI处方率77.8%→70.6%,β受体阻滞剂67.7%→74.2%,MRA 26.6%→35.5%。
- 1个月死亡率8.9%→7.6%,6个月死亡率24.7%→21.3%,匹配后HR 0.78(0.66-0.94)。
临床怎么用
- 应关注急性心衰合并症负担增加,优化急诊入院路径。
- 需提高射血分数降低患者出院时循证药物(尤其ACEI/ARB/ARNI)的处方率。
- 对高龄和射血分数保留患者需探索改善预后的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Real-life data is very useful for gaining a better understanding of care in practice and identifying areas for improvement. This study aimed to assess changes in the clinical characteristics, care and outcomes of patients hospitalised with acute heart failure (HF). METHODS: Two multicentre snapshot surveys were conducted in 2009 and 2021 following the same methodology and enrolled 1658 and 1513 patients, respectively. Clinical characteristics, hospitalisation pathways, in-hospital management and short-term outcomes during a 6-month follow-up were collected. RESULTS: While the age of patients and the proportion in each left ventricular ejection fraction (LVEF) category remained largely unchanged (76 years and 53% with reduced LVEF in the two surveys), there was a rise in the prevalence of most comorbidities. Emergency department was the predominant and increasing route for hospitalisation (64-71%), and admission to critical care units remained frequent and stable (40%). In patients with reduced LVEF, the prescription rate of ACE inhibitors, angiotensin receptor blockers or angiotensin receptor-neprilysin inhibitors (ARNis) decreased from 77.8% to 70.6%, while the use of beta-blockers and mineralocorticoid receptor antagonists increased (67.7-74.2% and 26.6-35.5%, respectively) at discharge. Mortality at 1 and 6 months declined from 8.9% to 7.6% and from 24.7% to 21.3%, respectively. This difference was also significant after matching the two cohorts (HR 0.78 (0.66-0.94)). This improvement in mortality was observed in most patients except in the most elderly and those with preserved LVEF. CONCLUSIONS: A comparison of two cross-sectional surveys of acute HF, conducted 12 years apart, reveals an increasing burden of comorbidities, as well as a lack of dedicated admission pathways and a significant shortcoming in the prescription of evidence-based HF drugs on discharge. However, there has been a significant decrease in short-term mortality. TRIAL REGISTRATION NUMBER: NCT01080937 and NCT05232058.
引用
- Logeart, Alos, Legallois, et al. Temporal trends in characteristics, management and prognosis of patients with acute heart failure through two repeated snapshots. Heart. 2026. PMID: 42128625. doi:10.1136/heartjnl-2025-327454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。